Showing 1621-1630 of 2314 results for "".
- Nicox Announces the Publication of Preclinical Efficacy Results on a New Class of Non-PGA NO-Donating IOP-Lowering Compoundshttps://modernod.com/news/nicox-announces-the-publication-of-preclinical-efficacy-results-on-a-new-class-of-non-pga-no-donating-iop-lowering-compounds/2478896/Nicox SA announced the publication of preclinical IOP-lowering results on a new class of non-prostaglandin analog (PGA), nitric oxide (NO)-donating compounds, in the Journal of Ocular Pharmacology and Therapeutics.1 The NO-mediated IOP-lowering effect in this new class of comp
- Single Dose of Pfizer, BioNTech’s COVID-19 Vaccine 85% Effective: Studyhttps://modernod.com/news/single-dose-of-pfizer-biontechs-covid-19-vaccine-85-effective-study/2478893/Study results published in The Lancet showed that a single dose of Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 is 85% effective at preventing symptomatic disease 15 to 28 days after being administered. The data, which come from an analysis of healthcare workers in Israel, also
- Surface Ophthalmics Announces First Patient Dosed in Phase 2 Trial for SURF-200 for Acute Dry Eyehttps://modernod.com/news/surface-ophthalmics-announces-first-patient-dosed-in-phase-2-trial-for-surf-200-for-acute-dry-eye/2478833/Surface Ophthalmics announced that the first patient has been dosed in the phase 2 clinical trial for its investigational product SURF-200 (betamethasone in Klarity vehicle) for the treatment of acute dry eye. In this dose-ranging study, SURF-200 will be studied in two different low concen
- Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401 for Thyroid Eye Diseasehttps://modernod.com/news/immunovant-announces-voluntary-pause-in-clinical-dosing-of-imvt-1401-for-thyroid-eye-disease/2478829/Immunovant announced a voluntary pause of dosing in its ongoing clinical trials of its investigational drug IMVT-1401 for the treatment of Thyroid Eye Disease (TED). The company has become aware of a physiological signal consisting of elevated total cholesterol and LDL levels
- J&J’s Single-Dose COVID-19 Vaccine 66% Effectivehttps://modernod.com/news/jjs-single-dose-covid-19-vaccine-66-effective/2478814/Johnson & Johnson reported topline results Friday showing that its investigational single-dose vaccine candidate Ad26.COV2.S met all primary and key secondary endpoints of the phase 3 ENSEMBLE study, with an overall efficacy rate of 66% at preventing moderate-to-severe COVID-19, 28 days after
- Surface Ophthalmics Announces First Patient Dosed in Head-to-Head Phase 2 Trial for SURF-100 for Chronic Dry Eye Diseasehttps://modernod.com/news/surface-ophthalmics-announces-first-patient-dosed-in-head-to-head-phase-2-trial-for-surf-100-for-chronic-dry-eye-disease/2478802/Surface Ophthalmics announced that the first patient has been dosed in the phase 2 clinical trial for its investigational product SURF-100 (mycophenolate sodium and betamethasone sodium phosphate in Klarity vehicle) for the treatment of chronic dry eye disease. SURF-100 utilizes a new an
- US to Bolster COVID-19 Vaccine Supply With Millions More Doses this Summerhttps://modernod.com/news/us-to-bolster-covid-19-vaccine-supply-with-millions-more-doses-this-summer/2478803/The Biden administration on Tuesday said it would boost the supply of coronavirus vaccines sent to states, tribes and territories by about 16% to a minimum of 10 million doses a week, for the next 3 weeks. According to the administration, this increase of 1.4 million doses per week will allow 
- DORC Announces Health Canada Approval of Tissueblue for Staining of the ILM During Vitreoretinal Surgeryhttps://modernod.com/news/dorc-announces-health-canada-approval-of-tissueblue-for-staining-of-the-ilm-during-vitreoretinal-surgery/2478799/DORC has announced that it has received notification from Health Canada that the application for Tissueblue (Brilliant Blue G Ophthalmic Solution 0.025%) has been approved and will be available later in 2021 via Innovamed, DORC’s local distributor partner. Tissueblue is the first dye approved by
- Early Study Shows J&J’s One-Dose COVID-19 Vaccine Triggered Antibodies in all Participantshttps://modernod.com/news/early-study-shows-jjs-one-dose-covid-19-vaccine-triggered-antibodies-in-all-participants/2478759/Detailed phase 1/2a study findings published in the NEJM on Wednesday showed that all volunteers given Johnson & Johnson’s single-dose coronavirus vaccine Ad26.COV2.S had detectable neutralizing antibodies by day 57. In September, the company reported a preview of the interim results in
- Biden Aims to Release All Available COVID-19 Vaccine Doses to Speed Up Distribution: Reporthttps://modernod.com/news/biden-aims-to-release-all-available-covid-19-vaccine-doses-to-speed-up-distribution-report/2478739/President-elect Joe Biden will seek to release nearly every available dose of the coronavirus vaccine when he takes office later this month, a move that signals a departure from the Trump administration and the FDA’s current stance of holding back half of the US vaccine supply in order to e